Rabbit Anti-Human DARS (a.a. 401-501) Polyclonal antibody

In this contribution, we present the results of a study of the Probability Density Function (PDF) of the state durations in satellite broadcasting systems. We show that a channel state model that uses a Markov state model of order one is not appropriate if the state duration is of high importance, which can be the case in the process of system planning. In this case, a dynamic higher order Markov state model can be used. We study the modeling of the channel state duration for both single and multiple satellite broadcasting systems. In case of multiple satellite systems the channel state modeling is performed based on a dynamic higher order Markov channel state model for joint processes that depends on the current state duration. This approach is able to model the channel states of the whole system correctly, as well as the channel states of each satellite observed independently, showing the ability of capturing the state correlation between multiple satellites. Moreover, we introduce a reduced complexity channel state generation algorithm based on the PDF of the state duration. Our channel state models are validated with measurements of the Satellite Digital Audio Radio Services (S-DARS) system XM Radio carried out on various locations in the USA and Canada.

Antibody-drug conjugates (ADCs) are designed to facilitate the targeted delivery of cytotoxic drugs to improve their tumor fighting effects and minimize systemic toxicity. However, efficacy and safety can potentially be compromised due to the release of conjugated drugs from the ADC with time while in circulation, resulting in changes in the drug-to-antibody ratio (DAR). Current understanding of this process is limited because existing methods such as immunoassays fail to distinguish ADCs with different DARs. Here we demonstrate a novel method with bead-based affinity capture and capillary liquid chromatography-mass spectrometry to allow direct measurement of drug release by quantifying DAR distributions of the ADC in plasma/serum. This method successfully identified individual intact conjugated antibody species produced due to drug loss from ADCs (e.g., an engineered site-specific anti-MUC16 THIOMAB-drug conjugate) and measured the corresponding DAR distributions in vitro and in vivo. Information obtained can provide insights into the mechanisms involved in drug loss and help to optimize ADC therapeutics. Other potential applications of the method may include characterization of posttranslational modifications, protein adducts, and immunogenicity. (C) 2011 Elsevier Inc. All rights reserved.